Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Financial Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Financial Select Sector SPDR Fund trades at $54.3 (market cap $50.96B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Financial Select Sector SPDR Fund's market cap, and Vertex Pharmaceuticals Incorporated is more actively traded (806,603 versus 35,821,731). Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| VRTX | XLF | |
|---|---|---|
Market Cap | $128.16B | $50.96B |
Volume | 806,603 | 35,821,731 |
Sector | Health | — |
52-Week High | $557.96 | $58.55 |
52-Week Low | $407.37 | $47.80 |
Typical Hold Time | 120 Days | 104 Days |
Enterprise Value | $122.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
XLF trades at $53.75, down 0.48% with a bearish technical signal as financial stocks lag the broader market. The ETF faces headwinds from rising interest rates and regulatory changes, though higher rates could benefit bank profitability. Recent news highlights sector rotation into financials by fund managers despite underperformance relative to the S&P 500.
The outlook remains cautious with technical indicators showing bearish momentum, though oversold conditions may present entry opportunities. Key risks include interest rate sensitivity and regulatory uncertainty, while potential catalysts include continued Fed tightening and improved bank earnings. Wall Street sentiment is mixed with institutional positioning favoring financials.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
